Johnson & Johnson Enters U.S. Soft-Tissue Robotic Surgery Market With FDA-Authorized Ottava
Johnson & Johnson has entered the U.S. soft-tissue robotic surgery market after receiving FDA De Novo authorization for its OTTAVA system. The table-integrated architecture was approved for multiple upper-abdominal procedures, including gastric bypass, gastrectomy, cholecystectomy, gastric sleeve surgery, appendectomy, and hiatal hernia repair, with a selective launch aimed at enabling training, workflow integration, and adequate procedure volumes.